OGG1

N-glycosylase/DNA lyase

7,002 patent compounds predicted against OGG1, 4,804 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1669270	0.67	2/20
SCHEMBL1669273	0.67	2/20
SCHEMBL1278875	0.58	2/20
SCHEMBL1023783	0.54	2/20
SCHEMBL684918	0.51	2/20
SCHEMBL2835832	0.50	2/20
SCHEMBL1639136	0.48	2/20
SCHEMBL1639137	0.48	2/20
SCHEMBL1639211	0.48	2/20
SCHEMBL1639215	0.48	2/20
SCHEMBL1814265	0.48	2/20
SCHEMBL315250	0.47	2/20
SCHEMBL1576887	0.44	2/20
SCHEMBL1604533	0.43	2/20
SCHEMBL520409	0.42	2/20
SCHEMBL958906	0.39	2/20
SCHEMBL38806	1.00	1/20
SCHEMBL343630	0.76	1/20
SCHEMBL2678949	0.76	1/20
SCHEMBL1886020	0.73	1/20

Germline variants in OGG1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full OGG1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to OGG1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer	PHASE2	COMPLETED
Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL)	PHASE2	COMPLETED
Satraplatin and Prednisone to Treat Prostate Cancer	PHASE2	COMPLETED
A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas	PHASE2	UNKNOWN
Olaparib in People With Malignant Mesothelioma	PHASE2	COMPLETED
Phase II ABT-888 With Cyclophosphamide	PHASE2	COMPLETED
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)	PHASE2	UNKNOWN
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)	PHASE2	NOT_YET_RECRUITING
N-Acetylcysteine Protection Against Radiation Induced Cellular Damage	PHASE2	COMPLETED
Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)	PHASE1/PHASE2	UNKNOWN
Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients	PHASE2	COMPLETED
Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer	PHASE2	RECRUITING
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer	PHASE2	ACTIVE_NOT_RECRUITING
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma	PHASE1	RECRUITING
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome	nan	UNKNOWN
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC	nan	UNKNOWN
DNA Adductomics for Colorectal Cancer Investigation	nan	UNKNOWN
Environmental Pollutants in COPD and Lung Cancer	nan	RECRUITING
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Determination of RNA/DNA Damage Associated With Oxidative Stress in Periodontitis Patients	nan	COMPLETED
Effects of Resistance Training Programes At Different Intensities on Musculoskeletal, Metabolic, Lipid, Immunological, Inflammatory, Well-being and Functional Parameters in Older Adults.	nan	COMPLETED
Comparison of Oxidants and Antioxidants in Breastmilk Under Different Anesthesia Protocols	nan	COMPLETED
Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy.	nan	UNKNOWN
Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews	nan	COMPLETED
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581	nan	COMPLETED
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)	nan	UNKNOWN
Vascular Senescence and Atherosclerotic Plaque Vulnerability	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a OGG1 binder may also engage these)

Protein	Name	Similarity
O08760	—	0.988	O08760 →
O70249	—	0.986	O70249 →
Q96FB5	—	0.936	Q96FB5 →
Q3T0A0	—	0.934	Q3T0A0 →
Q96FV2	—	0.934	Q96FV2 →
Q2TBI8	—	0.934	Q2TBI8 →
Q8VCA8	—	0.934	Q8VCA8 →
Q9UHB4	—	0.933	Q9UHB4 →
Q1JPJ0	—	0.932	Q1JPJ0 →
POLM	DNA-directed DNA/RNA polymerase mu	0.931	landscape →
Q8IZ69	—	0.930	Q8IZ69 →
Q8BNV1	—	0.929	Q8BNV1 →
Q9BRQ3	—	0.929	Q9BRQ3 →
Q5E9V4	—	0.929	Q5E9V4 →
Q91W89	—	0.928	Q91W89 →
Q9NTJ4	—	0.928	Q9NTJ4 →
Q5SUV1	—	0.927	Q5SUV1 →
Q60HD5	—	0.927	Q60HD5 →
PPM1F	Protein phosphatase 1F	0.926	landscape →
Q32PI0	—	0.926	Q32PI0 →
Q9DD16	—	0.926	Q9DD16 →
PPOX	Protoporphyrinogen oxidase	0.926	landscape →
Q501J2	—	0.926	Q501J2 →
Q6AYG0	—	0.926	Q6AYG0 →
Q6P9U1	—	0.925	Q6P9U1 →
Q9BQD7	—	0.925	Q9BQD7 →
Q6AYR8	—	0.925	Q6AYR8 →
Q96AZ1	—	0.924	Q96AZ1 →
Q8N9H8	—	0.924	Q8N9H8 →
O00587	—	0.924	O00587 →